Navigation Links
Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012

FARMINGTON, Conn., March 14, 2012 /PRNewswire-iReach/ -- Global Information Inc. is excited to announce 4 significant Drug Discovery and Healthcare conferences scheduled for Boston, MA in the Spring of 2012.

8th Annual PEGS, Protein Engineering Summit
April 30 – May 4, 2012: Cambridge Healthtech Institute is hosting the Eighth Annual PEGS: Protein Engineering Summit in Boston, MA. This comprehensive event encompasses 12 tracks, 15 short courses, and a preconference partnering forum for showcasing early stage companies. Topics span from early stage discovery of new methods for protein expression and antibody engineering, to improved analytical techniques, and clinical results in the most promising areas of biotechnology. There is tremendous momentum and investment in biologics, and PEGS offers an unparalleled view of the field.

Additional information and Early Bird discounted rates are available at

Next-Gen Kinase Inhibitors
June 4 - 6, 2012: Pioneers from across the rapidly maturing kinase inhibitors field will gather to explore the exciting question of what lies ahead at the Next-Gen Kinase Inhibitors Conference in Cambridge, MA. What is in store for the pharmaceutical industry and what new avenues are opening up for new technologies and methods as novel targets and therapeutic approaches are explored? What ground-breaking kinase indications are being discovered, and what other therapeutic areas are blossoming?

Topics to be explored include key issues around addressing resistance; selectivity versus safety; developing lead compounds; the integration of chemistry and biology; using promising techniques such as fragment and structure based design; optimizing PK and PD; and analyzing the flood of data available.

Additional information and Early Bird discounted rates are available at

CHI and Bio-IT World's 12th Annual Structure-Based Drug Design Conference
June 6 - 8, 2012: Structure-based drug design took nearly two decades of multiple, parallel technological improvements to arrive at its current mainstream position in medicinal chemistry. At the CHI and Bio-IT World's 12th Annual Structure-Based Drug Design Conference in Cambridge, MA, an accomplished faculty of experts will bring to focus recent advancements in this evolving and dynamic field. Developments in computer graphics, high-power radiation sources, computational processing power, refinement protocols, virtual screening and crystallography were all necessary to create the environment for rapid, iterative structure-based drug discovery. Given the crisis facing the pharmaceutical industry in the translation of early stage drug discovery results, a different set of tools, concerned with algorithms and methods for developing best in class drugs that engage biological targets with kinetically optimized potency and selectivity will need to be refined.

Additional information and Early Bird discounted rates are available at

Discover more biotechnology research and resources:

About Global Information Inc. Global Information (GII) ( is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia of Global Information, Inc., 1-860-674-8796,

News distributed by PR Newswire iReach:

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Media alert: Press registration open for 2012 SIR Annual Scientific Meeting
2. Air Force Office of Scientific Research hosts annual program Spring Review
3. Research!America Annual Advocacy Awards Dinner
4. Highlights of the Biophysical Society 56th Annual Meeting
5. Chinese scientists Zhen-Yi Wang and Zhu Chen awarded 7th annual Szent-Gyorgyi Prize
6. 2012 SSR Annual Meeting: Call for abstracts
7. Toxicologists annual meeting in San Francisco to showcase the latest scientific achievements
8. Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference
9. UH Seidman Cancer Center researchers present at American Society of Hematology Annual Meeting
10. NYU Langone experts present at American College of Rheumatology 2011 Annual Meeting
11. NJIT grad students display work at 7th annual Research Day on Nov. 9
Post Your Comments:
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology: